Karen Steindorf’s Post

Our article, "Report From the Second Global Scientific Conference on Clinical Trial Design and Outcome Measures for RDH12-Associated Inherited Retinal Degeneration," has just been published in the Translational Vision Science & Technology journal. This is a significant step forward for RDH12 research and the broader field of inherited retinal diseases. We’re proud to have worked with top scientists and advocates on this important project. Now, we’re focused on making the first-ever clinical trial for RDH12 a reality. Read it here: https://lnkd.in/e4D543DH #EyesOnTheFuture #RDH12 #ARVO

New from #EHA2024 | Final long-term follow-up results of the #RELAZA2 study: #MRD-guided treatment with aza in #MDS and #AML 🎥 🩸 Dr. Anne Sophie Kubasch, MD, University Hospital Leipzig, presents the final long-term follow-up results of the #RELAZA2study (NCT01462578), a Phase II trial investigating #measurableresidualdisease (#MRD)-guided treatment with #azacitidine (aza) in patients with #myelodysplasticsyndrome (#MDS) and #acutemyeloidleukemia (#AML) 🌟 #MRD responses were classified into major and minor, and those patients achieving a major response had significantly better survival outcomes than those with a minor response or no response 🌟 Dr Kubasch concludes that aza was able to prevent or delay #hematological relapse in the cohort of patients enrolled in this study Learn more 👉 https://lnkd.in/eREZtYYD #VJHemOnc #CLLsm #Leusm

Microphysiological Systems (MPS)...

Kudos to PI Dr. Khaled Ziada, along with Rachel Landis, Kelly Norris, Douglas Eckley, Danielle Kellner, Stephanie Stoianoff, Loretta Winstead, Mark Majchszak, Meghan Khebouz, and the entire MICRO2 study team at Cleveland Clinic for enrolling their first patient in the MICRO2 study! Dr. Ziada's first enrollments come on the heels of the formal publication of results from the pilot MICRO trial, where early data demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) with a simple 90-second, zero-contact scan. Dr. Ziada's team was a key contributor to the success of MICRO and now officially kickstarts their contribution to MICRO2, primarily designed to validate these results in a larger cohort of patients. We're thrilled by the opportunity to collaborate with Dr. Ziada and his colleagues as we further important research in both CMD and MCG together! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Please enjoy this conversation with Joanna Kempner on her new book, Psychedelic Outlaws! Clever, moving, and insightful - let me know what you think 🤓 https://lnkd.in/gVN7QDTg

Interested in what HCPs truly feel about your and/or your competitors new data? Pros? Cons? How they are thinking about including (or not including) in their future treatment armamentarium? How you can best message to assuage concerns? How perception trends change year over year? Oh - and do so innovatively, simply, quickly, and cost-effectively? Shameless plug ⬇

Matthew Howe, PhD, our principal partnerships manager, presented alongside Elisa L. Priest, Dr.P.H. and Ashley Dowell Hopkins, MBA from Baylor Scott & White Health at the Research and Innovation in Healthcare conference in Dallas, Texas on April 23rd. They discussed the collaboration between BSW and Owkin and how to practically integrate AI-driven methodologies to better understand cardiovascular disease. Learn more about how we work with partners to apply cutting-edge AI to multimodal data to better understand complex biology: https://lnkd.in/eCdTxADH

So proud, best presentation at IMAD2024! Joachim Sejr Skovbo Kristensen, MD, PhD student, took the first prize at this years IMAD symposium! He presented our surprising observation that the growth rate of AAA is half in AAA of The DANCAVAS trial compared to the VIVA AAA screening cohort. Smoking was similar, a bit more were diabetic, BMI was equal, - the only reason we can guess of is the prescriped statin was 40 mg of atorvastatin in the DANCAVAS trial compared to 40 mg Simvastin in the VIVA trial. An advanced Pharmacoepdiomogical registry study exploiting the unique access to the Danish nationwide registries is being set up for clarification.

🌎🔬 Don’t Miss AMRA Medical at ICFSR 2024! 🔬🌎 This week, the AMRA Medical team will be in attendance at the 14th annual International Conference on Frailty and Sarcopenia Research (ICFSR), where our scientists will be showcasing their latest insights into muscle composition's critical role in various health outcomes. The presentations demonstrate the utility of AMRA's MRI-based body composition analysis platform, AMRA® Researcher, in delivering novel biomarkers that describe overall muscle health. This innovative approach is transforming muscle composition research by enabling more personalized insights on function and performance. By advancing disease research in neuromuscular, metabolic diseases, and beyond, AMRA Medical continues to lead with cutting-edge MRI-powered analyses, offering more personalized insights for researchers, patients, and providers alike. Stay tuned for more updates on how we're advancing disease research with our precision imaging platform in sarcopenia and beyond! To get in touch or if you are attending and want to meet us at ICFSR, reach out to info@amramedical.com. #ICFSR2024 #AMRAMedical #MuscleComposition #ChronicKidneyDisease #Sarcopenia #precisionmedicine #neuromusculardisease #MRI #clinicalresearch

Proven (again). iFR guidance is safe. No difference in MACE. iFR is Class IA.